Trademark Search in Canada

ENGENSIS AND DESIGN

View On IC.GC.CA

REGISTERED

on 15 Oct 2021

Last Applicant/ Owned by

HELIXMITH CO. LTD

21, Magokjungang 8-ro 7-gilGangseo-guSeoul 07794

Serial Number

1904619 filed on 15^th Jun 2018

Registration Number

TMA1111609 registered on 15^th Oct 2021

Registration expiry Date

15^th Oct 2031

Correspondent Address

FASKEN MARTINEAU DUMOULIN LLP

800 rue du Square Victoria, bureau 3500Montréal,

QUEBEC

H4Z1E9

ENGENSIS AND DESIGN

Trademark usage description

genetic treatment preparations, namely biological preparations for use in gene therapy for the treatment of painful diabetic neuropathy, neuropathy, n Read More

Classification Information

Class [005]
Genetic treatment preparations, namely biological preparations for use in gene therapy for the treatment of painful diabetic neuropathy, neuropathy, neuromuscular disease, amyotrophic lateral sclerosis, spinal cord disease, motor neuron disease, neurodegenerative disease, critical limb ischemia, diabetic foot ulcer, ulcer, cardiovascular disease, peripheral vascular disease, peripheral arterial disease, myocardial ischemia, coronary artery disease, heart disease, arterial occlusive disease, infarction; reagents for use in veterinary genetic testing; reagents for use in medical genetic testing; diagnostic preparations for medical purposes for detecting mutation in prion genes; preparations for medical purposes for detecting mutation in prion genes; chemical preparations for pharmaceutical purposes, namely pharmaceutical preparations for the treatment of painful diabetic neuropathy, neuropathy, neuromuscular disease, amyotrophic lateral sclerosis, spinal cord disease, motor neuron disease, neurodegenerative disease, critical limb ischemia, diabetic foot ulcer, ulcer, cardiovascular disease, peripheral vascular disease, peripheral arterial disease, myocardial ischemia, coronary artery disease, heart disease, arterial occlusive disease, infarction; drugs for medical purposes, namely, prescription and non-prescription medicines, namely, pills, tablets, capsules, caplets, liquid drops, sachets and pharmaceutical preparations for the treatment of painful diabetic neuropathy, neuropathy, neuromuscular disease, amyotrophic lateral sclerosis, spinal cord disease, motor neuron disease, neurodegenerative disease, critical limb ischemia, diabetic foot ulcer, ulcer, cardiovascular disease, peripheral vascular disease, peripheral arterial disease, myocardial ischemia, coronary artery disease, heart disease, arterial occlusive disease, infarction; pharmaceutical drugs, namely, pharmaceutical preparations for the treatment of painful diabetic neuropathy, neuropathy, neuromuscular disease, amyotrophic lateral sclerosis, spinal cord disease, motor neuron disease, neurodegenerative disease, critical limb ischemia, diabetic foot ulcer, ulcer, cardiovascular disease, peripheral vascular disease, peripheral arterial disease, myocardial ischemia, coronary artery disease, heart disease, arterial occlusive disease, infarction; medicines for human purposes, pharmaceutical preparations for the treatment of painful diabetic neuropathy, neuropathy, neuromuscular disease, amyotrophic lateral sclerosis, spinal cord disease, motor neuron disease, neurodegenerative disease, critical limb ischemia, diabetic foot ulcer, ulcer, cardiovascular disease, peripheral vascular disease, peripheral arterial disease, myocardial ischemia, coronary artery disease, heart disease, arterial occlusive disease, infarction; pharmaceutical preparations for diagnosis of painful diabetic neuropathy, neuropathy, neuromuscular disease, amyotrophic lateral sclerosis, spinal cord disease, motor neuron disease, neurodegenerative disease, critical limb ischemia, diabetic foot ulcer, ulcer, cardiovascular disease, peripheral vascular disease, peripheral arterial disease, myocardial ischemia, coronary artery disease, heart disease, arterial occlusive disease, infarction; ethical medicinal preparations, namely, pharmaceutical preparations for the treatment of painful diabetic neuropathy, neuropathy, neuromuscular disease, amyotrophic lateral sclerosis, spinal cord disease, motor neuron disease, neurodegenerative disease, critical limb ischemia, diabetic foot ulcer, ulcer, cardiovascular disease, peripheral vascular disease, peripheral arterial disease, myocardial ischemia, coronary artery disease, heart disease, arterial occlusive disease, infarction; pharmaceutical preparations for the treatment of patients, namely pharmaceutical preparations for gene therapy; pharmaceutical preparations for the treatment of immune system related diseases and disorders; chemical preparations for use in medical DNA analysis

Classification kind code

Class [042]
Pharmaceutical research and development; pharmaceutical research services; consultancy relating to pharmaceutical research and development; research and development of vaccines and medicines; scientific research in the fields of biomedicine; research and testing services in the fields of bacteriology and virology; drug discovery services; research and development in the pharmaceutical and biotechnology fields; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; consultancy in analysis of biology sequence processing for medical research purposes; consultancy in analysis of genomics for medical research purposes; scientific research in the fields of medicine, health and pharmacology; analysis of human serum for medical research; analysis of human tissues for medical research; blood analysis services.

Classification kind code

Mark Details

Serial Number

1904619

Mark Type

Trademark

Legal History

Action Taken	Status
Submitted for opposition 42 on 26^th May 2021	Advertised
Submitted for opposition 26 on 29^th Apr 2021	Approved
Submitted for opposition 27 on 29^th Apr 2021	Approval Notice Sent
Submitted for opposition 22 on 5^th Nov 2020	Search Recorded
Submitted for opposition 20 on 5^th Nov 2020	Examiner's First Report
Submitted for opposition 135 on 22^nd May 2020	Amendment to Application
Submitted for opposition 135 on 17^th May 2019	Amendment to Application
Submitted for opposition 1 on 18^th Jun 2018	Created
Submitted for opposition 31 on 18^th Jun 2018	Formalized
Submitted for opposition 30 on 15^th Jun 2018	Filed